VIR Q3 2024 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-9.8% YoY

Gross Profit

-$193M-8102.9% margin

Operating Income

-$231M-9718.7% margin

Net Income

-$214M-8979.7% margin

EPS (Diluted)

$-1.56

QoQ Revenue Growth

-22.6%

Cash Flow

Operating Cash Flow

-$171M

Free Cash Flow

-$174M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$258M

Stockholders' Equity

$1.2B

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-9.8%
Gross Profit	-$193M	-$142M	-35.4%
Operating Income	-$231M	-$187M	-23.9%
Net Income	-$214M	-$163M	-30.8%

Revenue Segments

Grant

$2M60%

Contract Revenue

$1M40%